Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rimegepant - Biohaven Pharmaceuticals Holding Company

Drug Profile

Rimegepant - Biohaven Pharmaceuticals Holding Company

Alternative Names: BHV-3000; BMS-927711; Rimegepant sulfate; Rimegepant Zydis® ODT - Biohaven; Rimegepant Zydis® oral fast-dissolve tablet - Biohaven

Latest Information Update: 11 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Biohaven Pharmaceutical Holding Company
  • Class 2 ring heterocyclic compounds; Antimigraines; Cycloheptanes; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Migraine
  • Phase II Trigeminal neuralgia

Most Recent Events

  • 01 Nov 2019 FDA assigns PDUFA action date of the first quarter of 2020 for orally dissolving tablet formulation of Rimegepant for Migraine
  • 01 Nov 2019 Biohaven Pharmaceuticals plans a launch for Rimegepant in the first quarter of 2020
  • 09 Sep 2019 Additional efficacy data from a phase II/III trial in Migraine released by Biohaven Pharmaceutical Holding Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top